Related references
Note: Only part of the references are listed.T cell checkpoint regulators in the heart
Nir Grabie et al.
CARDIOVASCULAR RESEARCH (2019)
Potential cardiovascular implications of Janus kinase inhibitors in immune mediated diseases
Nehal N. Mehta
CARDIOVASCULAR RESEARCH (2018)
Vasculitis associated with immune checkpoint inhibitors-a systematic review
Anisha Daxini et al.
CLINICAL RHEUMATOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors It Is Now Time for Cardio-Immuno-Oncology
Carlo G. Tocchetti et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes
Shisuo Du et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Javid J. Moslehi et al.
LANCET (2018)
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti et al.
LANCET ONCOLOGY (2018)
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2018)
Cardiorenal complications of immune checkpoint inhibitors
Krishna Sury et al.
NATURE REVIEWS NEPHROLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors
Stephane Ederhy et al.
JACC-CARDIOVASCULAR IMAGING (2018)
Ipilimumab induced digital vasculitis
Amrita Padda et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune checkpoint inhibitors and cardiovascular toxicity
Alexander R. Lyon et al.
LANCET ONCOLOGY (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Immune Checkpoint Inhibitor Toxicity in 2018
Douglas B. Johnson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe-Elie Salem et al.
LANCET ONCOLOGY (2018)
Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors
Gilda Varricchi et al.
LANCET ONCOLOGY (2018)
Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature
Shagufta Shaheen et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)
Case Report of Ipilimumab-Induced Diffuse, Nonnecrotizing Granulomatous Lymphadenitis and Granulomatous Vasculitis
Kari Arellano et al.
JOURNAL OF PHARMACY PRACTICE (2018)
Exploring immune checkpoints as potential therapeutic targets in atherosclerosis
Pascal J. H. Kusters et al.
CARDIOVASCULAR RESEARCH (2018)
Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion
Igal Kushnir et al.
CARDIOLOGY (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
Sebastien Le Burel et al.
EUROPEAN JOURNAL OF CANCER (2017)
New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma
Juliane Behling et al.
MELANOMA RESEARCH (2017)
Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis
Hui Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
Antje Sucker et al.
NATURE COMMUNICATIONS (2017)
Plasma brain natriuretic peptide levels are elevated in patients with cancer
Sachiko Bando et al.
PLOS ONE (2017)
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
Marion Escudier et al.
CIRCULATION (2017)
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
Rebecca Y. Tay et al.
BRITISH JOURNAL OF CANCER (2017)
US Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer
Chana Weinstock et al.
CLINICAL CANCER RESEARCH (2017)
Immune checkpoint dysfunction in large and medium vessel vasculitis
Ryu Watanabe et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2017)
Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma
Mary E. Roth et al.
AMERICAN JOURNAL OF THERAPEUTICS (2016)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
Pericardial effusion with tamponade physiology induced by nivolumab
Jennifer Nesfeder et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Apical takotsubo syndrome in a patient with metastatic breast carcinoma on novel immunotherapy
Robert D. Anderson et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Polymyalgia Rheumatica and Giant Cell Arteritis A Systematic Review
Frank Buttgereit et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
Katrin Klocke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition
Rob R. H. van den Brom et al.
RHEUMATOLOGY (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity
Michael Hughes et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
2015 ESC Guidelines for the diagnosis and management of pericardial diseases The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS)
Yehuda Adler et al.
EUROPEAN HEART JOURNAL (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
Heinz Laeubli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome
Benjamin P. Geisler et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153
Babak Baban et al.
PLOS ONE (2015)
VISTA Is an Immune Checkpoint Molecule for Human T Cells
J. Louise Lines et al.
CANCER RESEARCH (2014)
The immune checkpoint inhibitors: where are we now?
Rachel Webster
NATURE REVIEWS DRUG DISCOVERY (2014)
Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4
Barbara L. Goldstein et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Retinal vasculitis and ocular vitreous metastasis following complete response to PD-I inhibition in a patient with metastatic cutaneous melanoma
Joshua S. Manusow et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
Alida L. P. Caforio et al.
EUROPEAN HEART JOURNAL (2013)
Tim-3 Expression Defines Regulatory T Cells in Human Tumors
Jing Yan et al.
PLOS ONE (2013)
Update on Myocarditis
Ingrid Kindermann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
Jian Wang et al.
INTERNATIONAL IMMUNOLOGY (2010)
BSR and BHPR guidelines for the management of giant cell arteritis
Bhaskar Dasgupta et al.
RHEUMATOLOGY (2010)
Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper
Matthias G. Friedrich et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3
Yoshinori Seko et al.
CARDIOVASCULAR RESEARCH (2007)
Healing after myocardial infraction
G Ertl et al.
CARDIOVASCULAR RESEARCH (2005)
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
N Watanabe et al.
NATURE IMMUNOLOGY (2003)
Case reports of heart failure after therapy with a tumor necrosis factor antagonist
HJ Kwon et al.
ANNALS OF INTERNAL MEDICINE (2003)
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice
T Okazaki et al.
NATURE MEDICINE (2003)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Share Paper
